ASH 2025
Amir Fathi, MD, on Newly Diagnosed AML: Azacitidine and Venetoclax vs Conventional Induction Chemotherapy
Amir Fathi, MD, of Massachusetts General Hospital, discusses data from the phase II PARADIGM trial, which prospectively tested whether azacitidine plus venetoclax was superior to intensive induction c...
Othman Al-Sawaf, MD, PhD, on Previously Untreated CLL: Fixed-Duration vs Continuous Targeted Treatment
Othman Al-Sawaf, MD, PhD, of the University Hospital of Cologne, presents results from the phase III CLL17 trial, which compared continuous ibrutinib monotherapy to fixed-duration venetoclax plus obin...
Fixed-Duration Doublet Noninferior to Continuous Ibrutinib in CLL
Early results from the CLL17 trial show that fixed-duration doublet regimens with venetoclax are noninferior to continuous ibrutinib therapy, with similar 3-year progression-free survival rates, for p...
Anand Patel, MD, on Ph-Positive ALL: TKI Plus Inotuzumab Ozogamicin–Based Therapy
Anand Patel, MD, of the University of Chicago, discusses results from a phase II trial that showed tyrosine kinase inhibitor plus inotuzumab ozogamicin–based therapy resulted in major molecular respon...
Ibrahim Aldoss, MD, on Older Adults With B-Cell ALL: CD19 CAR T-Cell Therapy
Ibrahim Aldoss, MD, of City of Hope, presents findings from a small, single-center study of patients aged 55 years and older with B-cell acute lymphoblastic leukemia (ALL) in first complete remission ...
Valeria Santini, MD, on Imetelstat for Lower-Risk MDS: Long-Term Outcomes From the IMerge Trial
The telomerase inhibitor imetelstat was approved for the treatment of certain patients with lower-risk myelodysplastic syndromes (MDS) based on the results of the phase III IMerge trial. Valeria Santi...
Jayastu Senapati, MBBS, on B-Cell ALL: Brexucabtagene Autoleucel as Consolidation Therapy
Jayastu Senapati, MBBS, of The University of Texas MD Anderson Cancer Center, presents initial results from a phase II trial of brexucabtagene autoleucel as consolidation therapy in front-line high-ri...
Aaron Logan, MD, PhD, on Relapsed/Refractory B-Cell ALL: Real-World Data on Brexucabtagene Autoleucel and Transplant
Aaron Logan, MD, PhD, of UCSF Health, discusses research examining the effect of transplant before or after treatment with brexucabtagene autoleucel in the real world for adult patients with relapsed ...
Jack Khouri, MD, on Multiple Myeloma: Burixafor and Propranolol With G-CSF Before Transplant
Jack Khouri, MD, of Cleveland Clinic, describes the findings of a phase II trial which investigated the safety and efficacy of burixafor (GPC-100), a potent and selective small -molecule antagonist of...
